Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Why Is Preterm Birth Risk Kit Focused Sera Prognostics Stock Trading Higher Today?

Author: Vandana Singh | December 06, 2023 11:13am

Sera Prognostics Inc (NASDAQ:SERA) announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal PRIME study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis

The company has adopted the DSMB's recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data.

Sera offers the PreTRM Test, a blood-based biomarker test that provides an early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.

"It is unexpected for trials to stop early for efficacy since most statistical power is typically reserved for the final analysis, which makes this event that much more encouraging," said Zhenya Lindgardt, President and CEO of Sera Prognostics.

Sera Prognostics stock is gaining on heavy volume, with a session volume of 30.85 million shares traded, compared to the trailing 100-day volume of 36.12k shares, according to data from Benzinga Pro.

Price Action: SERA shares are up 234.80% at $7.03 on the last check Wednesday.

Posted In: SERA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist